"10.1371_journal.pone.0108722","plos one","2014-09-30T00:00:00Z","Bauke Schievink; Hiddo Lambers Heerspink; Hubert Leufkens; Dick De Zeeuw; Jarno Hoekman","Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands; Medicines Evaluation Board, Utrecht, The Netherlands","Conceived and designed the experiments: BS HLH HL DDZ JH. Performed the experiments: BS JH. Analyzed the data: BS JH. Contributed reagents/materials/analysis tools: JH. Wrote the paper: BS JH HLH. Reviewed manuscript: BS HLH HL DDZ JH.","HLH has consultancy agreements with the following companies: AbbVie, Astellas, Johnson & Johnson, Reata, and Vitae. All honoraria are paid to his employer/institution University of Groningen. DDZ is a consultant for and received honoraria (to employer/institution) from AbbVie, Astellas, AstraZeneca, Chemocentryx, J&J, Hemocue, Novartis, Reata, Takeda, and Vitae. HL is chairman of the Dutch Medicines Evaluation Board; the views in this paper are not necessarily the views of the MEB. This study was funded by TI Pharma. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","09","Bauke Schievink","BS",5,TRUE,5,2,2,3,TRUE,TRUE,FALSE,0,NA,FALSE
